Description
Shipping Notice. Orders for Tesamorelin require 7–14 business days for processing and fulfillment prior to shipment. Please plan research timelines accordingly. For order status inquiries, contact [email protected].
CAS # 218949-48-5 Sequence (trans-3-hexenoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 — 44 amino acids Molecular Formula C221H366N72O67S Molecular Weight ~5135.86 Da PubChem ID 16137828
History
Tesamorelin (designated TH9507 in early research literature) is a synthetic analog of endogenous human growth hormone-releasing hormone (GHRH), comprising the full 44-amino acid sequence of GHRH(1–44) with a trans-3-hexenoic acid group covalently linked to the N-terminal tyrosine residue. The compound was developed by Theratechnologies Inc. (Montreal, Canada) and first described in peer-reviewed literature in the context of dipeptidylpeptidase-4 (DPP-4) resistance: native GHRH is rapidly cleaved in circulation by DPP-4 at the Tyr1–Ala2 bond, and the N-terminal hexenoyl modification was structurally characterized as blocking this cleavage site, preserving the intact GHRH(1–44) sequence for hypothalamic-pituitary receptor interaction in preclinical models. This mechanistic characterization established the compound’s research relevance as a structurally stabilized GHRH analog for investigation of the somatotropic axis.
Grunfeld C, Dritselis A, Kirkpatrick P. (2011) [PubMed]
Spooner LM, Olin JL. (2012) [PubMed]
Quality Verification — USA Third-Party Testing
Every batch of A2Z Tesamorelin undergoes independent verification at USA-based analytical laboratories for identity (mass spectrometry) and purity (reversed-phase HPLC, typical purity ≥98%). Batch-specific Certificates of Analysis are available with each order.
Research Findings
Tesamorelin has been studied in hypothalamic-pituitary axis signaling, hepatic metabolic pathway, and body composition research models, with peer-reviewed laboratory literature characterizing its interactions with GHRH receptor binding mechanisms, pulsatile GH secretion dynamics, and IGF-1 axis modulation in preclinical and controlled investigational settings.
Falutz J et al., 2010 [PubMed]
Key Areas of Research:
Molecular GHRH(1–44) receptor binding characterization, DPP-4 cleavage resistance via N-terminal trans-3-hexenoyl modification, somatotropic axis receptor interaction modeling, peptide structural stability assays
Cellular / Endocrine Pituitary somatotroph signaling pathway characterization, IGF-1 axis modulation patterns, pulsatile GH secretion parameter assessment, GH pulse amplitude and frequency measurement in research models
Systemic (Preclinical) Visceral adipose tissue compartment modeling, circulating lipid parameter profiling, hepatic steatosis research contexts, metabolic substrate monitoring in controlled investigational settings
Together, these findings suggest broad experimental potential for Tesamorelin across hypothalamic-pituitary axis, adipose tissue compartment, and hepatic pathway research contexts. For complete references, consult primary publications on PubMed.
Stanley TL et al., 2011 [PubMed]
Storage and Handling (Laboratory Use Only)
Store lyophilized material at -20°C or below, protected from light. Reconstitute using standard laboratory protocols appropriate to the investigator’s experimental design.
References
Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291–304. [PubMed] Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150–8. [PubMed] Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011;10(2):95–6. [PubMed] Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240–7. [PubMed]
For Research Use Only (RUO). Not for human consumption, diagnostic, therapeutic, or veterinary use. Researchers are responsible for compliance with all applicable laws and institutional regulations. Read our RUO Policy